Abigail Brooks, MA

Results identified mesangial IgM deposition as an independent risk factor for ESKD in patients with IgAN, particularly in advanced disease stages.

Our February 2024 month in review highlights some of our top hepatology content from the past few weeks, including pipeline updates, phase 2/3 trial data, and new research in liver diseases.

Jairath discusses disease clearance and optimal treatment targeting in UC, highlighting what the ongoing VERDICT trial hopes to add to our understanding of improving patient outcomes.

Results showed 95.8% of patients who were treated for HCV with DAA therapy and underwent renal transplantation did not experience HCV recurrence.

Positive topline results show apraglutide outperformed placebo for relative change from baseline in actual weekly parenteral support volume at week 24 in adults with SBS-IF.

Our February 2024 month in review highlights EoE pipeline news, new FMT guidelines, and research about endoscopic inflammation and disease activity in IBD.

Inflammatory markers, infliximab levels, and physician global assessment scores remained similar when assessed pre- and post-switch to an infliximab biosimilar.

Dubinsky discusses the importance of head-to-head trials in IBD and looks ahead to the use of combination therapy to achieve desired treatment outcomes.

Results suggest a high prevalence of fatty liver in adults with chronic HCV, which was significantly associated with central obesity, elevated blood pressure, and metabolic syndrome.

Younger gestational age, lower birthweight, and a more severe initial AKI episode were identified as risk factors for recurrent AKI, which was linked to extended hospitalization.

Cross-sectional survey results suggest most providers are recommending HCV screening based on patient risk factors rather than universally for all patients 18-79 years of age.

NAFLD, ALD, liver fibrosis and cirrhosis, and recently diagnosed viral hepatitis were all associated with a greater risk of cataract.

Dubinsky discusses findings from a post-hoc analysis of the head-to-head SEQUENCE trial of risankizumab versus ustekinumab in patients with Crohn disease refractory to anti-TNF therapy.

All patients who received an HCV+ organ achieved SVR12 and had lower rates of rejection and chronic lung allograft dysfunction compared to uninfected donor organ recipients.

Zhang discusses the consequences of stigmatizing language for substance use disorders and reasons gastroenterologists and hepatologists may be falling behind.

Results from the phase 3 trial showed seladelpar elicited biochemical response, normalized alkaline phosphatase, and reduced pruritus at a greater rate than placebo.

Investigators from the guideline panel discuss the AGA’s recommendations regarding the use of fecal microbiota-based therapies for CDI, IBD, and IBS.

The guideline recommends fecal microbiota transplant in most cases of recurrent Clostridioides difficile infection but does not suggest fecal microbiota-based therapies for IBD or IBS.

Adhering to a greater number of healthy lifestyle behaviors was linked to a decreased risk of incident IBS, suggesting lifestyle modifications may help prevent its onset.

Retreatment with voxilaprevir/velpatasvir/sofosbuvir in patients with HCV and prior DAA failure is effective but may be impacted by hepatocellular carcinoma, cirrhosis, and genotype 3.

Histological inflammation and clinical IBD activity were both associated with reduced fertility rates compared to histological remission and quiescent IBD.

Findings suggest segregated residential and transplant center neighborhoods contribute to racial disparities in access to living donor kidney transplantation.

The incidence of KRT for primary glomerular disease-induced kidney failure was greatest for IgA nephropathy and focal segmental glomerulosclerosis.

Stigmatizing language was found on 88% of transplant center websites and was most prevalent when discussing alcohol-associated hepatitis and cirrhosis.

Results confirmed the cost-effectiveness of Japan’s mandated school urinary screening strategy, also pointing to fewer patients progressing to ESKD compared to no screening.

Nearly 30% of patients were receiving potentially inappropriately prescribed medications at the start of the study and more than 20% were still receiving these medications 1 year later.

The review explored the global epidemiology of HCV in patients on dialysis, providing novel estimations of its prevalence and case fatality rate in this patient population.

Marla Dubinsky, MD, discusses the use of off-label upadacitinib in pediatric IBD patients and the importance of this research due to delays in pediatric drug approvals.

The investigational antisense oligonucleotide’s designation is based on data from the phase 2b trials B-Clear and B-Sure.

HealthFLD, a fully automated AI software for liver attenuation analysis from CT scans, has received FDA 510(k) clearance for use in the general population.